Preclinical characterization of quizartinib and AC886, a metabolite of quizartinib, in AML models, and anti-leukemic activity of quizartinib on midostaurin-resistant AML cells-MedSci.cn

Preclinical characterization of quizartinib and AC886, a metabolite of quizartinib, in AML models, and anti-leukemic activity of quizartinib on midostaurin-resistant AML cells

Aikawa, T; Togashi, N; Iwanaga, K; Okada, H; Nishiya, Y; Inoue, S; Levis, MJ; Isoyama, T

CANCER RESEARCH, 2019; 79 (13):

科室
- - 订阅+
  - 更多科室
工具
服务